Open Access Highly Accessed Study protocol

A randomized, phase III trial of capecitabine plus bevacizumab (Cape-Bev) versus capecitabine plus irinotecan plus bevacizumab (CAPIRI-Bev) in first-line treatment of metastatic colorectal cancer: The AIO KRK 0110 Trial/ML22011 Trial

Clemens Giessen, Ludwig Fischer von Weikersthal, Axel Hinke, Sebastian Stintzing, Frank Kullmann, Ursula Vehling-Kaiser, Julia Mayerle, Markus Bangerter, Claudio Denzlinger, Markus Sieber, Christian Teschendorf, Jens Freiberg-Richter, Christoph Schulz, Dominik Paul Modest, Nicolas Moosmann, Philipp Aubele and Volker Heinemann*

BMC Cancer 2011, 11:367  doi:10.1186/1471-2407-11-367

Article Metrics

7993
Total accesses

Article metric FAQ

Accesses  

  • Last 30 days: 68 accesses
  • Last 365 days: 1073 accesses
  • All time: 7993 accesses

These numbers are accesses on BioMed Central websites only, and an underestimate of total usage. More information